IL94448A - Stable frozen-dry composition of ether / ester polymatoporphyrin - Google Patents
Stable frozen-dry composition of ether / ester polymatoporphyrinInfo
- Publication number
- IL94448A IL94448A IL9444890A IL9444890A IL94448A IL 94448 A IL94448 A IL 94448A IL 9444890 A IL9444890 A IL 9444890A IL 9444890 A IL9444890 A IL 9444890A IL 94448 A IL94448 A IL 94448A
- Authority
- IL
- Israel
- Prior art keywords
- freeze
- dried
- product
- solution
- phe
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 title claims description 16
- 150000002148 esters Chemical class 0.000 title claims description 14
- 238000000034 method Methods 0.000 claims abstract description 23
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 22
- 238000002428 photodynamic therapy Methods 0.000 claims abstract description 7
- -1 porphyrin compounds Chemical class 0.000 claims abstract description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 32
- 239000000243 solution Substances 0.000 claims description 28
- 238000004108 freeze drying Methods 0.000 claims description 22
- 239000011780 sodium chloride Substances 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical class CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 claims description 4
- 150000002170 ethers Chemical class 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229960003569 hematoporphyrin Drugs 0.000 claims 2
- 231100000760 phototoxic Toxicity 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000012141 concentrate Substances 0.000 description 11
- 239000002245 particle Substances 0.000 description 8
- 150000004032 porphyrins Chemical class 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000003504 photosensitizing agent Substances 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 238000004166 bioassay Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000008121 dextrose Substances 0.000 description 5
- 239000008355 dextrose injection Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000004067 bulking agent Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229940109328 photofrin Drugs 0.000 description 2
- 230000002165 photosensitisation Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940025708 injectable product Drugs 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000013627 low molecular weight specie Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229950003776 protoporphyrin Drugs 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000013022 venting Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/366,374 US5059619A (en) | 1989-06-14 | 1989-06-14 | Stable freeze-dried polyhematoporphyrin ether/ester |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL94448A0 IL94448A0 (en) | 1991-03-10 |
| IL94448A true IL94448A (en) | 1994-06-24 |
Family
ID=23442747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL9444890A IL94448A (en) | 1989-06-14 | 1990-05-20 | Stable frozen-dry composition of ether / ester polymatoporphyrin |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US5059619A (cs) |
| EP (1) | EP0402637B1 (cs) |
| JP (1) | JP3112918B2 (cs) |
| KR (1) | KR0164845B1 (cs) |
| CN (1) | CN1058388C (cs) |
| AR (1) | AR244549A1 (cs) |
| AT (1) | ATE144703T1 (cs) |
| AU (1) | AU625549B2 (cs) |
| CA (1) | CA2018751C (cs) |
| CZ (1) | CZ283309B6 (cs) |
| DD (1) | DD295087A5 (cs) |
| DE (1) | DE69029012T2 (cs) |
| DK (1) | DK0402637T3 (cs) |
| ES (1) | ES2095846T3 (cs) |
| FI (1) | FI101597B (cs) |
| GR (1) | GR3021511T3 (cs) |
| HU (1) | HU215522B (cs) |
| IE (1) | IE902137A1 (cs) |
| IL (1) | IL94448A (cs) |
| NO (1) | NO176645C (cs) |
| NZ (1) | NZ233953A (cs) |
| PL (1) | PL164744B1 (cs) |
| PT (1) | PT94344B (cs) |
| RU (1) | RU2019990C1 (cs) |
| TW (1) | TW225475B (cs) |
| ZA (1) | ZA904599B (cs) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5418130A (en) | 1990-04-16 | 1995-05-23 | Cryopharm Corporation | Method of inactivation of viral and bacterial blood contaminants |
| US6187572B1 (en) | 1990-04-16 | 2001-02-13 | Baxter International Inc. | Method of inactivation of viral and bacterial blood contaminants |
| PL165249B1 (pl) * | 1991-10-29 | 1994-11-30 | Wojskowa Akad Tech | Sposób otrzymywania soli kompleksowych hematoporfiryny i jej pochodnych PL PL PL PL PL PL PL |
| US5244914A (en) * | 1992-04-27 | 1993-09-14 | American Cyanamid Company | Stable porfimer sodium compositions and methods for their manufacture |
| NO180167C (no) | 1994-09-08 | 1997-02-26 | Photocure As | Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol |
| US5660181A (en) * | 1994-12-12 | 1997-08-26 | Physical Optics Corporation | Hybrid neural network and multiple fiber probe for in-depth 3-D mapping |
| GB9512854D0 (en) * | 1995-06-23 | 1995-08-23 | Wellcome Found | Novel formulation |
| US5958104A (en) * | 1997-09-11 | 1999-09-28 | Nonomura; Arthur M. | Methods and compositions for enhancing plant growth |
| CA2221912A1 (en) * | 1997-11-21 | 1999-05-21 | David Dolphin | Photosensitizers with improved biodistribution and light-absorbing properties |
| ES2445579T3 (es) | 2000-11-29 | 2014-03-04 | Pci Biotech As | Internalización fotoquímica para el suministro de moléculas mediado por virus en el citosol |
| CZ301427B6 (cs) | 2000-11-29 | 2010-02-24 | Pci Biotech As | Zpusob zavedení molekuly do cytosolu bunky |
| US7175611B2 (en) | 2002-06-05 | 2007-02-13 | Mark Alan Mitchnick | Antimicrobial release system |
| RU2223963C1 (ru) * | 2002-06-25 | 2004-02-20 | Московская государственная академия тонкой химической технологии им. М.В. Ломоносова | Способ получения производного гематопорфирина |
| CN103961323B (zh) * | 2013-02-05 | 2017-10-17 | 浙江海正药业股份有限公司 | 一种注射用hpph冻干粉针制剂及其制备方法 |
| US9733187B2 (en) * | 2015-03-06 | 2017-08-15 | King Saud University | Method of detecting bladder cancer by optical analysis of bodily fluids |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2858320A (en) * | 1956-04-02 | 1958-10-28 | Baxter Laboratories Inc | Stable hematoporphyrin |
| US4649151A (en) * | 1982-09-27 | 1987-03-10 | Health Research, Inc. | Drugs comprising porphyrins |
| US4753958A (en) * | 1985-02-07 | 1988-06-28 | University Of Cal | Photochemotherapy of epithelial diseases with derivatives of hematoporphyrins |
| EP0210351B1 (en) * | 1985-04-30 | 1993-07-21 | Nippon Petrochemicals Co., Ltd. | Use of porphyrin derivatives in the detection and treatment of tumours |
| US4882234A (en) * | 1986-11-12 | 1989-11-21 | Healux, Inc. | Storage-stable porphin compositions and a method for their manufacture |
| US4968715A (en) * | 1988-07-06 | 1990-11-06 | Health Research, Inc. | Use of purified hematoporphyrin trimers in photodynamic therapy |
-
1989
- 1989-06-14 US US07/366,374 patent/US5059619A/en not_active Expired - Lifetime
-
1990
- 1990-05-14 EP EP90109031A patent/EP0402637B1/en not_active Expired - Lifetime
- 1990-05-14 AT AT90109031T patent/ATE144703T1/de not_active IP Right Cessation
- 1990-05-14 DE DE69029012T patent/DE69029012T2/de not_active Expired - Lifetime
- 1990-05-14 ES ES90109031T patent/ES2095846T3/es not_active Expired - Lifetime
- 1990-05-14 DK DK90109031.6T patent/DK0402637T3/da active
- 1990-05-17 TW TW079103997A patent/TW225475B/zh active
- 1990-05-20 IL IL9444890A patent/IL94448A/en not_active IP Right Cessation
- 1990-06-05 CN CN90104366A patent/CN1058388C/zh not_active Expired - Lifetime
- 1990-06-06 NZ NZ233953A patent/NZ233953A/en unknown
- 1990-06-11 JP JP02150078A patent/JP3112918B2/ja not_active Expired - Lifetime
- 1990-06-11 CZ CS902889A patent/CZ283309B6/cs not_active IP Right Cessation
- 1990-06-12 PT PT94344A patent/PT94344B/pt not_active IP Right Cessation
- 1990-06-12 CA CA002018751A patent/CA2018751C/en not_active Expired - Lifetime
- 1990-06-13 ZA ZA904599A patent/ZA904599B/xx unknown
- 1990-06-13 KR KR1019900008676A patent/KR0164845B1/ko not_active Expired - Lifetime
- 1990-06-13 PL PL90285633A patent/PL164744B1/pl unknown
- 1990-06-13 FI FI902966A patent/FI101597B/fi active IP Right Grant
- 1990-06-13 NO NO902634A patent/NO176645C/no not_active IP Right Cessation
- 1990-06-13 AU AU57089/90A patent/AU625549B2/en not_active Expired
- 1990-06-13 AR AR90317109A patent/AR244549A1/es active
- 1990-06-13 IE IE213790A patent/IE902137A1/en not_active IP Right Cessation
- 1990-06-13 RU SU904830142A patent/RU2019990C1/ru active
- 1990-06-14 HU HU903850A patent/HU215522B/hu unknown
- 1990-06-14 DD DD90341641A patent/DD295087A5/de unknown
-
1996
- 1996-10-31 GR GR960402151T patent/GR3021511T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5059619A (en) | Stable freeze-dried polyhematoporphyrin ether/ester | |
| EP0568323B1 (en) | Stable porfimer sodium compositions and methods for their manufacture | |
| CA2227761C (en) | Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizers | |
| PL205982B1 (pl) | Liofilizowany preparat zawierający przeciwciała przeciw receptorowi EGF oraz sposób jego otrzymywania | |
| PL201172B1 (pl) | Pd-Bakteriofeoforbid, sposób jego wytwarzania, kompozycja farmaceutyczna zawierająca go i jego zastosowanie | |
| RU2157225C2 (ru) | Флавано-лигнановая композиция и лекарственное средство на ее основе | |
| CN111848512A (zh) | 使用高纯度盐酸罂粟碱制备粉针剂药物组合物 | |
| ES2292781T3 (es) | Formulacion galenica inyectable para utilizar en un diagnostico o una terapia fotodinamica y su procedimiento de preparacion. | |
| EP4308076B1 (en) | Stable formulations of indocyanine green | |
| CN116997325B (zh) | 稳定的吲哚菁绿制剂 | |
| CN117062597A (zh) | 稳定的吲哚菁绿制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| EXP | Patent expired |